These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1720 related articles for article (PubMed ID: 32027846)

  • 1. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
    Sequist LV; Han JY; Ahn MJ; Cho BC; Yu H; Kim SW; Yang JC; Lee JS; Su WC; Kowalski D; Orlov S; Cantarini M; Verheijen RB; Mellemgaard A; Ottesen L; Frewer P; Ou X; Oxnard G
    Lancet Oncol; 2020 Mar; 21(3):373-386. PubMed ID: 32027846
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
    Yoh K; Hirashima T; Saka H; Kurata T; Ohe Y; Hida T; Mellemgaard A; Verheijen RB; Ou X; Ahmed GF; Hayama M; Sugibayashi K; Oxnard GR
    Target Oncol; 2021 May; 16(3):339-355. PubMed ID: 33939068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer.
    Yang JJ; Fang J; Shu YQ; Chang JH; Chen GY; He JX; Li W; Liu XQ; Yang N; Zhou C; Huang JA; Frigault MM; Hartmaier R; Ahmed GF; Egile C; Morgan S; Verheijen RB; Mellemgaard A; Yang L; Wu YL
    Invest New Drugs; 2021 Apr; 39(2):477-487. PubMed ID: 33052556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
    Oxnard GR; Yang JC; Yu H; Kim SW; Saka H; Horn L; Goto K; Ohe Y; Mann H; Thress KS; Frigault MM; Vishwanathan K; Ghiorghiu D; Ramalingam SS; Ahn MJ
    Ann Oncol; 2020 Apr; 31(4):507-516. PubMed ID: 32139298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tepotinib plus osimertinib in patients with EGFR-mutated non-small-cell lung cancer with MET amplification following progression on first-line osimertinib (INSIGHT 2): a multicentre, open-label, phase 2 trial.
    Wu YL; Guarneri V; Voon PJ; Lim BK; Yang JJ; Wislez M; Huang C; Liam CK; Mazieres J; Tho LM; Hayashi H; Nhung NV; Chia PL; de Marinis F; Raskin J; Zhou Q; Finocchiaro G; Le AT; Wang J; Dooms C; Kato T; Nadal E; Hin HS; Smit EF; Wermke M; Tan D; Morise M; O'Brate A; Adrian S; Pfeiffer BM; Stroh C; Juraeva D; Strotmann R; Goteti K; Berghoff K; Ellers-Lenz B; Karachaliou N; Le X; Kim TM;
    Lancet Oncol; 2024 Aug; 25(8):989-1002. PubMed ID: 39089305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and Rationale for a Phase II, Randomized, Open-Label, Two-Cohort Multicenter Interventional Study of Osimertinib with or Without Savolitinib in De Novo MET Aberrant, EGFR-Mutant Patients with Advanced Non-Small-Cell Lung Cancer: The FLOWERS Trial.
    Li A; Chen HJ; Yang JJ
    Clin Lung Cancer; 2023 Jan; 24(1):82-88. PubMed ID: 36333268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study.
    Goss G; Tsai CM; Shepherd FA; Bazhenova L; Lee JS; Chang GC; Crino L; Satouchi M; Chu Q; Hida T; Han JY; Juan O; Dunphy F; Nishio M; Kang JH; Majem M; Mann H; Cantarini M; Ghiorghiu S; Mitsudomi T
    Lancet Oncol; 2016 Dec; 17(12):1643-1652. PubMed ID: 27751847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
    Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
    Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.
    Jones RDO; Petersson K; Tabatabai A; Bao L; Tomkinson H; Schuller AG
    Mol Cancer Ther; 2023 May; 22(5):679-690. PubMed ID: 36888921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial.
    Wu YL; Cheng Y; Zhou J; Lu S; Zhang Y; Zhao J; Kim DW; Soo RA; Kim SW; Pan H; Chen YM; Chian CF; Liu X; Tan DSW; Bruns R; Straub J; Johne A; Scheele J; Park K; Yang JC;
    Lancet Respir Med; 2020 Nov; 8(11):1132-1143. PubMed ID: 32479794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON.
    Hartmaier RJ; Markovets AA; Ahn MJ; Sequist LV; Han JY; Cho BC; Yu HA; Kim SW; Yang JC; Lee JS; Su WC; Kowalski DM; Orlov S; Ren S; Frewer P; Ou X; Cross DAE; Kurian N; Cantarini M; Jänne PA
    Cancer Discov; 2023 Jan; 13(1):98-113. PubMed ID: 36264123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report.
    Yang JC; Shepherd FA; Kim DW; Lee GW; Lee JS; Chang GC; Lee SS; Wei YF; Lee YG; Laus G; Collins B; Pisetzky F; Horn L
    J Thorac Oncol; 2019 May; 14(5):933-939. PubMed ID: 30763730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial.
    Akamatsu H; Katakami N; Okamoto I; Kato T; Kim YH; Imamura F; Shinkai M; Hodge RA; Uchida H; Hida T
    Cancer Sci; 2018 Jun; 109(6):1930-1938. PubMed ID: 29697876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial.
    Akamatsu H; Toi Y; Hayashi H; Fujimoto D; Tachihara M; Furuya N; Otani S; Shimizu J; Katakami N; Azuma K; Miura N; Nishino K; Hara S; Teraoka S; Morita S; Nakagawa K; Yamamoto N
    JAMA Oncol; 2021 Mar; 7(3):386-394. PubMed ID: 33410885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive
    Yu HA; Paz-Ares LG; Yang JC; Lee KH; Garrido P; Park K; Kim JH; Lee DH; Mao H; Wijayawardana SR; Gao L; Hozak RR; Chao BH; Planchard D
    Clin Cancer Res; 2021 Feb; 27(4):992-1002. PubMed ID: 33046516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
    Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
    Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osimertinib for Japanese patients with T790M-positive advanced non-small-cell lung cancer: A pooled subgroup analysis.
    Hirashima T; Satouchi M; Hida T; Nishio M; Kato T; Sakai H; Imamura F; Kiura K; Okamoto I; Kasahara K; Uchida H; Vowler SL; Mitsudomi T
    Cancer Sci; 2019 Sep; 110(9):2884-2893. PubMed ID: 31265163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study.
    Ahn MJ; Han JY; Lee KH; Kim SW; Kim DW; Lee YG; Cho EK; Kim JH; Lee GW; Lee JS; Min YJ; Kim JS; Lee SS; Kim HR; Hong MH; Ahn JS; Sun JM; Kim HT; Lee DH; Kim S; Cho BC
    Lancet Oncol; 2019 Dec; 20(12):1681-1690. PubMed ID: 31587882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprogression Outcomes for Osimertinib versus Standard-of-Care EGFR-TKI in Patients with Previously Untreated EGFR-mutated Advanced Non-Small Cell Lung Cancer.
    Planchard D; Boyer MJ; Lee JS; Dechaphunkul A; Cheema PK; Takahashi T; Gray JE; Tiseo M; Ramalingam SS; Todd A; McKeown A; Rukazenkov Y; Ohe Y
    Clin Cancer Res; 2019 Apr; 25(7):2058-2063. PubMed ID: 30659024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 86.